arlutz73
- Bristol Myers Squibb (NYSE:BMY) said that phase 3 data on Sotyktu (deucravacitinib) indicated that the tyrosine kinase 2 (TYK2) inhibitor met its primary endpoint in patients with psoriatic arthritis who had never received a biologic disease-modifying antirheumatic drug (bDMARD).
- A